---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-024937"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:49:45.570823+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adial Pharma reports FY2022 net loss $12.7M, cash $4.0M; advances AD04 regulatory meetings

## Summary
- Net loss $12.7M for FY2022 vs $19.4M in FY2021; cash and equivalents $4.0M.
- R&D expenses down 50% to $4.2M; G&A down 2% to $9.3M.
- ONWARD Phase 3: AD04 significantly reduced heavy drinking days in heavy drinkers; identified two target genotypes.
- Secured meetings with FDA, Swedish MPA, German BfArM in Q2 2023 for AD04 approval path.
- Option to sell Purnovate to Adovate; potential milestones up to $83M plus 19.9% equity stake.

## SEC filing metadata
- accession: 0001213900-23-024937
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390023024937/0001213900-23-024937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390023024937/ea176126-8k_adialpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-024937
- JSON: https://secwatch.observer/filing/0001213900-23-024937.json
- Plain text: https://secwatch.observer/filing/0001213900-23-024937.txt

## Key facts
- Earnings Releases
  ADIAL PHARMACEUTICALS, INC. reported the 2022 fiscal year ended December 31, 2022 results: net income $12.7 million.
  - Period: the 2022 fiscal year ended December 31, 2022
  - Net income: $12.7 million
  - Result: reported results
  source text: Net Loss was $12.7 million for the year ended December 31, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390023024937/0001213900-23-024937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.